Breast cancer only pharma pipeline with over 1,000 drug in development

The breast cancer treatment pipeline’s exceptional levels of activity and innovation, with a staggering 1,050 drugs in active development across all stages and 347 first-in-class programs, may significantly alter the clinical and commercial landscape of the disease market over the next decade.

According to business intelligence provider GBI Research’s latest report, factors driving such innovation and potential for breakthrough drugs include a very large and growing patient pool, a well-established market with multiple unmet needs, and a robust understanding of the disease pathophysiology, facilitating the development of novel compounds that may fill such needs.

Dominic Trewartha, managing analyst for GBI Research, explains: “Breast cancer has the largest product pipeline in the pharmaceutical industry, and its significant patient population and successful commercialization of drugs such as Herceptin have attracted a great deal of R&D investment. The sheer number of first-in-class products in development reflects a deepening scientific understanding of the underlying pathophysiology of breast cancer and a growing list of molecules that have been implicated in the initiation and progression of the disease.”